Avivagen Inc. (VIVXF)
Avivagen Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Ottawa, ON, CA. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $7,769. On trailing twelve-month figures it carries a trailing P/E of -0.11, a net margin of -645.9%. Its beta of 0.36 implies it has historically moved less than the broad market.
Avivagen Inc. is a life sciences firm primarily engaged in creating and distributing specialized feed supplements for livestock. These products are designed to bolster animals' immune function and contribute to their enhanced growth and overall productivity. The company's diverse product portfolio includes OxC-beta Livestock, a key additive for animal feeds, alongside canine wellness offerings such as Vivamune and Dr. Tobias dog chews. Furthermore, Avivagen provides the Dr. Tobias Beta blend, formulated to support the human immune system. With a significant international footprint, Avivagen serves customers across the United States, Canada, the Philippines, Taiwan, Thailand, China, Mexico, Brazil, and Malaysia. The company was established in 2005 and is headquartered in Ottawa, Canada.
Avivagen Inc. is most often compared with the following Healthcare names: